Dystonia, A Disorder Longing for More Therapies
The Pediatric Movement Disorders Neurologist at UT Southwestern recommends that when encountering a patient with a movement disorder to organize your thought process in 3 steps.
Treatment With Antidiabetic Medications Shows Effect on Alzheimer Disease Genetic Expression
The compromised microvascular and insulin receptor signaling pathways seen in Alzheimer disease have been shown to be reduced or normalized by exposure to antidiabetic therapies.
Searching for a Biomarker in MS: Neurofilament Light Chain
The medical director of clinical development at Biogen spoke about the current use of the biomarker and the steps being taken clinically validate it.
Kate Davis, MD, MSTR: Referring Patients to An Epileptologist
The epileptologist discussed this challenge, and shared her thoughts on how to maintain this communication.
Immune System Reconstitution in Multiple Sclerosis With Cladribine Tablets
The director of the Comprehensive Multiple Sclerosis Center at Thomas Jefferson University provided insight on the potential effect cladribine could have on multiple sclerosis.
AMBAR Data Revealed Significant Reduction in the Progress of Alzheimer Disease
Trial results showed a reduction of 61% in disease progression in both primary efficacy endpoints measuring cognition and activities of daily living at 14 months.
Neurology Comic: How Do I Change My Genes?
I have Huntington disease in my family. How do I change my genes?
Claire Henchcliffe, MD, DPhil: Dopaminergic Cell Replenishment in Parkinson Disease
The associate professor of neurology and neuroscience at Weill Cornell Medicine discussed this work, and what she and her colleagues believe could be addressed by a successful effort.
Tideglusib Improves Myotonic Dystrophy Type 1 Neuromuscular Symptoms
In its second phase 2 trial, the therapy, also known as AMO-02, resulted in improvements in cognitive function, fatigue, and neuromuscular symptoms.
The Impact of CGRP Inhibitors on Patients and Providers
The president of the American Headache Society shared her thoughts on how preventive medicines can alter migraine treatment for the better.
When Your Patients Have Recurrent Dreams
People of all ages occasionally report recurrent dreams, and there is an established association between negative dreams and daytime anxiety.
Bernd Feige, PhD: Insomnia and the REM Sleep State
The study presents direct evidence that subjective experiences of insomnia may be coupled to the REM sleep state.
Spinal Muscular Atrophy, Questions That Remain Unanswered
Darryl De Vivo, MD, emphasized that while there's been a tremendous advance in the field of SMA, it’s important to continue tinkering around the margins to make the effective treatment increasingly better.
Zonisamide Improves Parkinsonism in Dementia with Lewy Bodies
Zonisamide improved Parkinsonism as an adjunct to levodopa in patients with dementia with Lewy bodies in phase 3 trial.
George Koshy Vilanilam, MBBS: Migraine as a Risk Factor for Ischemic Stroke
The study found that there has been a significant increasing trend in patients with migraine—irrespective of aura status—having an ischemic stroke.
FDA Approves Expanded Use for Sodium Oxybate in Cataplexy, Excessive Daytime Sleepiness in Pediatric Narcolepsy
Sodium oxybate is the first therapy approved to treat cataplexy or excessive daytime sleepiness in pediatrics with narcolepsy 7 years of age and older.
Lingering Unmet Needs in Acute Migraine Treatment
Despite the explosion of preventive medications for migraine, a large need for acute care remains.
Spinal Muscular Atrophy, From Bench to Bedside
The Sidney Carter Professor of Neurology at Columbia University Medical Center spoke about the 127 year history of spinal muscular atrophy and how basic science has led to exciting developments.
Customized Injections Enhance Botulinum Toxin for Essential Hand Tremor
Customizing injection sites and amounts of botulinum toxin for different presentations of essential hand tremor has been shown to avoid hand weakness.
Anna Heidbreder, MD: Anti-IgLON5 Disease, REM Sleep Behavior Disorder
Heidbreder further described the current understanding of the condition and what she and her colleagues have found out.
Peter Calabresi, MD: Utilizing A Uniform Biomarker Assay
For the director of the Johns Hopkins Multiple Sclerosis Center, a biomarker is perhaps only as useful as the clinician community’s ability to read out its measurements.
Continuing Research Into the Biology of Migraine
With many advancements in treatments occurring in recent years, the president of the American Headache Society urged for further research to continue to light the way.
Novel Deep Brain Stimulation System, ITI-214 Safe for Parkinson Disease, Elizabeth Ross on the Field's Progress
Neurology News Network for the week of Oct. 27, 2018.
Higher Concentration ANAVEX 2-73 Displays Positive Effect on Patients With Alzheimer Disease
As well as showing a positive impact on patient daily living and cognitive decline, data also confirmed SIGMAR1 and COMT as biomarkers of response to the therapy.
Epileptic Seizure Cycles Found to be Patient-Specific, Robust
The authors suggested that the detection and tracking of seizure cycles on a patient-specific basis should be standard in epilepsy management practices.
Thorsten Mikoteit, MD: Sleep Research, an Excellent Source for Biomarkers
The Psychiatrist at Psychiatric Services Solothurn and University of Basel discussed how heart rate variability correlates with sleep stages, which may indicate nocturnal brain activity.
PDE-10A Inhibitor For Huntington Disease Found Safe, Not Efficacious
A phase 2 trial demonstrating a PDE-10A inhibitor to be safe but not efficacious for Huntington disease could be followed with the testing of a higher dose.
Ubrogepant Shows Promise in Addressing Unmet Needs in Acute Care of Migraine
Allergan is planning a 2019 NDA submission to the FDA for its agent, ubrogepant, based on a pair of new trials.
Case Report: Urgent Surgery for Stroke
Symptoms of sudden onset of headache and decreased balance three days earlier prompted a visit to the emergency department.
BAN2401 Displays Promising Effect on Alzheimer Disease Progression
Within the defined amyloid-tau-neurodegeneration framework of Alzheimer disease, the investigational agent has displayed a hopeful effect on all 3 pieces.